New Zealand markets closed

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1,131.50-19.06 (-1.66%)
At close: 04:00PM EDT
1,132.25 +0.75 (+0.07%)
After hours: 05:36PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 124.76B
Enterprise value 117.65B
Trailing P/E 29.96
Forward P/E 23.20
PEG ratio (5-yr expected) 1.54
Price/sales (ttm)9.60
Price/book (mrq)4.42
Enterprise value/revenue 8.72
Enterprise value/EBITDA 23.04

Trading information

Stock price history

Beta (5Y monthly) 0.12
52-week change 335.75%
S&P500 52-week change 320.52%
52-week high 31,211.20
52-week low 3769.19
50-day moving average 31,110.96
200-day moving average 3979.87

Share statistics

Avg vol (3-month) 3457.88k
Avg vol (10-day) 3420.28k
Shares outstanding 5108.42M
Implied shares outstanding 6110.23M
Float 8103.45M
% held by insiders 11.53%
% held by institutions 189.82%
Shares short (15 Aug 2024) 42.11M
Short ratio (15 Aug 2024) 44.43
Short % of float (15 Aug 2024) 42.02%
Short % of shares outstanding (15 Aug 2024) 41.91%
Shares short (prior month 15 Jul 2024) 41.89M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)30 Jun 2024

Profitability

Profit margin 32.04%
Operating margin (ttm)30.83%

Management effectiveness

Return on assets (ttm)7.62%
Return on equity (ttm)16.55%

Income statement

Revenue (ttm)13.49B
Revenue per share (ttm)125.83
Quarterly revenue growth (yoy)12.30%
Gross profit (ttm)N/A
EBITDA 4.52B
Net income avi to common (ttm)4.32B
Diluted EPS (ttm)37.80
Quarterly earnings growth (yoy)47.90%

Balance sheet

Total cash (mrq)9.81B
Total cash per share (mrq)90.88
Total debt (mrq)2.7B
Total debt/equity (mrq)9.58%
Current ratio (mrq)5.44
Book value per share (mrq)261.41

Cash flow statement

Operating cash flow (ttm)4.07B
Levered free cash flow (ttm)2.09B